Medicenna Therapeutics Corp (MDNA) — Cash Flow-to-Debt Ratio
Medicenna Therapeutics Corp (MDNA) has a Cash Flow-to-Debt Ratio of -0.72x as of December 2025, meaning its operating cash flow of CA$-4.96 Million could theoretically repay -1% of its total liabilities (CA$6.85 Million) in one year. Check MDNA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Medicenna Therapeutics Corp Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Medicenna Therapeutics Corp across 12 annual periods. Also explore Medicenna Therapeutics Corp asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Medicenna Therapeutics Corp (2014–2025)
Year-by-year debt coverage analysis for Medicenna Therapeutics Corp. For market capitalisation and broader financial context, see MDNA company net worth.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.78x | CA$-16.49 Million | CA$9.29 Million | ▼ -52.3% |
| 2024 | -1.17x | CA$-16.26 Million | CA$13.94 Million | ▲ +35.9% |
| 2023 | -1.82x | CA$-12.66 Million | CA$6.96 Million | ▲ +79.8% |
| 2022 | -9.00x | CA$-23.58 Million | CA$2.62 Million | ▼ -141.4% |
| 2021 | -3.73x | CA$-15.31 Million | CA$4.11 Million | ▲ +23.1% |
| 2020 | -4.85x | CA$-8.95 Million | CA$1.85 Million | ▼ -55.1% |
| 2019 | -3.13x | CA$-8.04 Million | CA$2.57 Million | ▲ +31.7% |
| 2018 | -4.58x | CA$-10.12 Million | CA$2.21 Million | ▼ -390.2% |
| 2017 | -0.93x | CA$-7.31 Million | CA$7.83 Million | ▼ -27.4% |
| 2016 | -0.73x | CA$-2.57 Million | CA$3.51 Million | ▲ +75.7% |
| 2015 | -3.02x | CA$-880.32K | CA$291.87K | ▼ -304.1% |
| 2014 | -0.75x | CA$-619.44K | CA$829.89K | — |